Collecting data for bladder cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to create a comprehensive databank for patients diagnosed with urothelial cancer by collecting demographic, clinical, pathological, and follow-up data. Patients will provide informed consent for their data to be used in future research, which will help validate existing nomograms for predicting cancer recurrence and progression. The data collection will utilize electronic case report forms developed in accordance with established guidelines. This initiative is expected to enhance the understanding and management of bladder cancer treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* who are aged between 18-90,
* who are of male or female sex,
* who give their informed consent to collect their clinical and pathological data,
* who are planned to undergo TURBT for BC,
* who are planned to undergo (salvage) radical cystectomy with or without an extended pelvic lymph node dissection,
* who are planned to undergo tumor biopsy (from primary or metastatic tumor),
* who are planned to undergo radical nephroureterectomy ± partial cystectomy or segmental ureterectomy, with or without a lymph node dissection,
* who are planned to undergo endoscopic tumor biopsy or resection,
* from whom metastases will be surgically removed.

Exclusion Criteria:

* patients who do not give their informed consent to collect their clinical and pathological data,
* patients who withdraw their informed consent to use their clinical and pathological data,
* patients who refuse the planned treatment,
* women who are pregnant or have suspicion of pregnancy.

Where it's running

• University Hospitals Leuven
  Leuven, Vlaams-Brabant, Belgium Recruiting

Study contacts

• Principal investigator: Steven Joniau, MD, PhD — Assistant Professor
• Study coordinator: Murat Akand, MD
• Email: murat.akand@uzleuven.be
• Phone: +3216346687

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Inactivated UPEC-FimON for Bladder Cancer After BCG or Intravesical Therapy Failure

  This phase 1 study tests whether intravesical doses of inactivated UPEC-FimON are safe and tolerable in adults with non-muscle invasive bladder cancer that progressed after BCG or intravesical therapy.

  Recruiting at 3 sites Phase 1 Hopec Pharma · Kfar Saba, Central District and 2 other locations · NCT07881666

• Alpha1H before bladder tumor surgery in low/intermediate risk non-muscle-invasive bladder cancer

  This trial tests whether putting Alpha1H directly into the bladder before standard surgery helps prevent cancer from coming back or getting worse in adults with low- to intermediate-risk non-muscle-invasive bladder cancer.

  Recruiting Phase 3 Hamlet Pharma AB · Prague · NCT07804056

• Understanding how high-risk non-muscle-invasive bladder cancer is diagnosed and cared for in Portugal

  This study looks at how patients with high-risk non-muscle-invasive bladder cancer have been diagnosed and treated in regular care in Portugal.

  Recruiting Janssen-Cilag Farmaceutica Ltda. · Lisbon · NCT07784387

• Benchmarking AI language models against tumor boards for oncology treatment decisions

  This project tests whether frontier AI language models can match the treatment recommendations of multidisciplinary tumor boards for common cancers using standardized synthetic cases.

  Recruiting Assistance Publique - Hôpitaux de Paris · Boulogne-Billancourt and 4 other locations · NCT07739121

• Real-world look at high-risk non-muscle-invasive bladder cancer after BCG in Korea

  This study tests how people with high-risk non-muscle-invasive bladder cancer fare after BCG therapy in real-world clinical settings in Korea.

  Recruiting Janssen Korea, Ltd., Korea · Suwon · NCT07735793

• Enfortumab vedotin plus pembrolizumab versus chemoradiotherapy for muscle-invasive bladder cancer

  This trial tests whether combining enfortumab vedotin with pembrolizumab can help people with non-metastatic muscle-invasive bladder cancer keep their bladder and control the cancer better than standard concurrent chemoradiotherapy.

  Recruiting at 29 sites Phase 3 Astellas Pharma Inc · Little Rock, Arkansas and 28 other locations · NCT07566156

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.